生物标志物
乳腺癌
免疫疗法
癌症
医学
癌症研究
癌症免疫疗法
PD-L1
肿瘤科
内科学
生物
生物化学
作者
Malina Xiao,Caroline Duhem,Anwar Chammout,Guy Berchem,Bassam Janji
摘要
Programmed death-ligand 1 (PD-L1) expression has long been used as a biomarker to stratify patients with cancer who will benefit from anti-PD-1/PD-L1 immunotherapy. However, the use of PD-L1 as a biomarker to guide treatment decisions has recently been called into question due to its dynamic and heterogeneous expression within each tumor and among different tumors as well as during tumor cell plasticity. Therefore, understanding the molecular basis of PD-L1 expression would enable delineating its value as a reliable biomarker in the clinic. Here, we provide our perspective on the involvement of CMTM6 and CMTM7 as new lead candidates for the regulation of PD-L1 in breast tumors undergoing an epithelial to mesenchymal transition.
科研通智能强力驱动
Strongly Powered by AbleSci AI